For decades, Alzheimer's research has chased one toxic protein while another waited in the shadows. Now an experimental drug called diranersen, developed by Biogen and presented at a major international conference in London this week, offers a quieter kind of intervention — not a battle against tau tangles already formed, but a gentle instruction to the brain to produce less tau from the start. In a field where progress has been measured in small increments, a 26 percent slowing of cognitive decline in some patients signals that the long search for a second front in this disease may finally be
Experimental Alzheimer's drug targets tau protein with promising early results
By reducing tau production, the brain's cleanup systems have more capacity to clear what remains
Mark
Why does tau matter so much if amyloid is already the focus of treatment?
Mimi
Because amyloid alone doesn't cause Alzheimer's. You can have amyloid buildup in your brain for decades without symptoms. It's tau tangles that seem to flip the switch — to actually trigger the cognitive decline people experience. So if you can slow tau formation, you're potentially intervening at a different, critical point in the disease.
Mark
But why has tau been so hard to drug compared to amyloid?
Mimi
Partly because tau is more complex. It exists in many different forms, and only certain abnormal versions are toxic. Amyloid is more straightforward to target. Diranersen sidesteps that complexity by not trying to clear tau at all — it just tells the brain to make less of it from the start.
Mark
The study missed its main goal but still looks promising. How do researchers interpret that?
Mimi
It's genuinely puzzling. They expected a dose-response relationship — more drug, more benefit. Instead the lowest dose worked best. That's counterintuitive and suggests they don't fully understand the mechanism yet. But the cognitive slowdown was real and measurable, so they're not dismissing it.
Mark
What about the side effects — temporary confusion after injection?
Mimi
It's manageable compared to what some Alzheimer's drugs cause. The confusion lasts about a week and then resolves. More importantly, there's no brain inflammation, which is a real concern with anti-amyloid drugs. That's a meaningful safety advantage.
Mark
Is this the only new approach being tested?
Mimi
Not at all. There's a tau vaccine in trials now, a cholesterol drug that might help people with genetic risk, and technologies to get drugs across the blood-brain barrier more effectively. The field is finally moving beyond amyloid-only thinking.
Mark
What happens next?
Mimi
Biogen runs a larger confirmatory trial. UCSF's platform study expands. We'll know within a few years whether tau-targeting actually works at scale. If it does, the real question becomes whether combining tau and amyloid approaches works better than either alone.
The Pulse
- Alzheimer's has resisted treatment in part because its second key villain, tau, has remained nearly impossible to target — until now.
- Diranersen's trial produced an unexpected twist: the lowest dose outperformed higher ones, causing the study to technically miss its primary goal even as its results turned heads across the field.
- The drug's delivery method — injected directly into spinal fluid — bypasses the blood-brain barrier entirely, sidestepping one of neuroscience's most stubborn obstacles.
- Biogen is pressing forward with larger trials, while UCSF's newly launched Alzheimer's Tau Platform is already testing tau vaccines and combination therapies in parallel.
- Researchers are also pursuing cholesterol drugs and iron-molecule transport technologies as complementary routes, suggesting the field is converging on a multi-pronged assault on the disease.
For decades, Alzheimer's research has chased one toxic protein while another waited in the shadows. Now an experimental drug called diranersen, developed by Biogen and presented at a major international conference in London this week, offers a quieter kind of intervention — not a battle against tau tangles already formed, but a gentle instruction to the brain to produce less tau from the start. In a field where progress has been measured in small increments, a 26 percent slowing of cognitive decline in some patients signals that the long search for a second front in this disease may finally be opening.
For years, Alzheimer's drug development has orbited around amyloid, one of two toxic proteins believed to drive the disease. The other, tau, has remained stubbornly out of reach — until a new experimental drug called diranersen, developed by Biogen, offered a different kind of answer. Rather than attacking tau tangles already lodged in the brain, the drug works upstream, instructing the gene responsible for tau production to simply make less of it.
Presented this week at the Alzheimer's Association International Conference in London, findings from a study of roughly 400 people with mild cognitive impairment or early Alzheimer's showed that diranersen reduced tau levels and, in one group of patients, slowed cognitive decline by 26 percent compared to placebo — a result comparable to what today's amyloid-targeting drugs achieve. The drug is delivered by injection into the cerebrospinal fluid, giving it more direct access to the brain than intravenous alternatives, and its side effects — injection site discomfort and brief confusion in some patients — were notably milder than the brain inflammation sometimes caused by anti-amyloid therapies.
The trial carried an unexpected complication: Biogen had anticipated that higher doses would yield stronger results, but the lowest dose proved most effective. This inverted the study's assumptions and meant it technically failed its primary endpoint. Still, the results were compelling enough that Biogen is moving toward larger confirmatory trials.
The momentum extends well beyond one company. The University of California, San Francisco, last week launched the Alzheimer's Tau Platform, an NIH-funded initiative that will test multiple tau-fighting strategies — beginning with a vaccine called AADvac1 — both independently and alongside existing amyloid drugs. Researchers are also examining whether obicetrapib, a cholesterol-lowering drug in development for heart disease, might reduce Alzheimer's risk in people carrying the APOE4 gene, which influences both cholesterol metabolism and disease susceptibility. Separately, Denali Therapeutics is developing a method to ferry drugs across the blood-brain barrier by attaching them to iron molecules that naturally make the crossing.
Alzheimer's affects more than 7 million Americans and tens of millions worldwide. Current treatments offer only modest relief. If tau-targeting therapies prove out, they could give patients a genuinely new tool — and open the door to combination approaches that attack the disease from multiple directions at once.
Researchers have long known that Alzheimer's disease involves two toxic proteins working in tandem inside the brain. One is amyloid, which has become the focus of recent drug development. The other is tau, which has proven far more elusive to target. Now an experimental drug called diranersen, developed by Biogen, appears to offer a new path forward — not by attacking tau directly, but by telling the brain to make less of it in the first place.
The findings come from a study of roughly 400 people with mild cognitive impairment or early-stage Alzheimer's, presented this week at the Alzheimer's Association International Conference in London. Researchers found that diranersen did more than simply reduce tau levels in the brain. It also slowed the rate at which patients' cognitive abilities declined. In one subset of participants receiving the lowest dose, the slowdown was substantial enough to rival the effects seen in trials of today's amyloid-targeting drugs — a 26 percent reduction in cognitive decline compared to those given placebo.
What makes this approach distinctive is its mechanism. Diranersen is an antisense oligonucleotide, a type of molecule that doesn't battle existing tau tangles but instead instructs the gene responsible for tau production to dial back output. By reducing the amount of tau the brain manufactures, the theory goes, the brain's natural cleanup systems have an easier time clearing away what tau does accumulate. The drug is delivered via injection directly into the cerebrospinal fluid surrounding the spinal cord — a more direct route to the brain than the intravenous infusions used for current Alzheimer's treatments.
The study did contain a surprise. Biogen had expected that higher doses would produce stronger benefits, but the opposite proved true. The lowest dose, administered twice yearly, showed the most promise. This unexpected result meant the trial technically failed to meet its primary goal, yet the findings were encouraging enough that Biogen is moving forward with larger studies to confirm the drug's value. Side effects were generally manageable: injection site pain and temporary confusion lasting about a week in some cases, but notably absent was the brain inflammation that can accompany anti-amyloid therapies.
The tau field is heating up beyond Biogen's work. The University of California, San Francisco, last week launched the Alzheimer's Tau Platform, a National Institutes of Health-funded initiative designed to test multiple experimental tau-fighting approaches, both alone and in combination with existing amyloid drugs. The first candidate is a vaccine called AADvac1, which trains the immune system to recognize and attack a specific problematic form of tau. The platform model will expand to other sites and eventually include people who carry Alzheimer's-related protein buildup but haven't yet developed symptoms.
Researchers are also exploring unexpected angles of attack. A cholesterol-lowering drug called obicetrapib, currently in development for heart disease, may have relevance for Alzheimer's because the gene that raises genetic risk for the disease, APOE4, also influences how the body processes cholesterol. NewAmsterdam Pharma plans to test whether lowering cholesterol in people carrying this gene might also reduce their Alzheimer's risk. Meanwhile, other companies are working to help drugs penetrate the blood-brain barrier more effectively — Denali Therapeutics, for instance, is developing a technology that allows drugs to hitch a ride on iron molecules that naturally cross into the brain.
Alzheimer's affects more than 7 million Americans and tens of millions of people worldwide. The disease's underlying biology remains incompletely understood, but the prevailing model suggests that amyloid buildup begins silently years before symptoms appear, eventually triggering the formation of tau tangles that spark cognitive decline. Current treatments can only modestly slow that decline. The emergence of tau-targeting approaches, if they prove effective, could offer patients a genuinely different tool — and perhaps, eventually, a way to attack the disease from multiple angles at once.
Notable Quotes
This is really quite promising if it were to hold up in larger testing— Jessica Langbaum, Banner Alzheimer's Institute
I think it will reinvigorate interest and investment in lots of tau mechanisms, and the field needs that— Dr. Reisa Sperling, Mass General Brigham
Want the full story?
Read the original at Santa Ana Orange County Register ↗
Health & Medicine